Results 191 to 200 of about 10,825 (231)
Some of the next articles are maybe not open access.
SSRIs vs. SNRIs for anxiety and OCD
The Brown University Child and Adolescent Behavior Letter, 2020Selective serotonin reuptake inhibitors (SSRIs) have greater adverse event (AE)–related discontinuation of treatment than serotonin‐norepinephrine reuptake inhibitors (SNRIs) in the treatment of pediatric obsessive‐compulsive disorder (OCD) and anxiety disorders. And SSRIs are more likely than SNRIs to produce “activation” (restlessness).
openaire +1 more source
Channelling of SSRIs and SNRIs use in the Tayside population, Scotland
Pharmacoepidemiology and Drug Safety, 2007AbstractPurposeTo compare the user profiles of the two classes of drug, using the Tayside Medicines Monitoring Unit (MEMO) record‐linkage database.MethodsA cohort study was carried out in the population of Tayside in Scotland. A total of 13 901 selective serotonin re‐uptake inhibitor (SSRI) users and 1417 selective norepinephrine re‐uptake inhibitor ...
Wei, Li +2 more
openaire +3 more sources
Pharmacological Profile of SSRIs and SNRIs in the Treatment of Eating Disorders
Current Clinical Pharmacology, 2009Bulimia Nervosa (BN) and Binge Eating Disorder (BED) are some of the most common eating disorders (ED) in industrialized societies, characterized by uncontrolled binge eating and self-induced purging or other compensatory behaviours aiming to prevent body weight gain.
CAPASSO, Anna, PETRELLA C, MILANO W.
openaire +3 more sources
Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome
Cochrane Database of Systematic Reviews, 2013Fibromyalgia syndrome (FMS) is a clinically well-defined chronic condition of unknown etiology characterized by chronic widespread pain that often co-exists with sleep disturbances, cognitive dysfunction and fatigue. Patients often report high disability levels and poor quality of life (QOL).
Winfried, Häuser +4 more
openaire +2 more sources
Qualitative review of SNRIs in anxiety.
The Journal of clinical psychiatry, 2005Anxiety disorders pose a problem for a significant number of individuals, with a 1-year prevalence rate estimated at 13.1% to 17.1%. Many pharmacologic agents have been used to treat anxiety disorders, and among those in current use are newer benzodiazepines (alprazolam), azapirones (buspirone), selective serotonin reuptake inhibitors (paroxetine and ...
openaire +1 more source